JP2015522659A - 夜尿症のための医薬製剤およびその使用の方法 - Google Patents

夜尿症のための医薬製剤およびその使用の方法 Download PDF

Info

Publication number
JP2015522659A
JP2015522659A JP2015524292A JP2015524292A JP2015522659A JP 2015522659 A JP2015522659 A JP 2015522659A JP 2015524292 A JP2015524292 A JP 2015524292A JP 2015524292 A JP2015524292 A JP 2015524292A JP 2015522659 A JP2015522659 A JP 2015522659A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
release
analgesics
formulated
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015524292A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522659A5 (https=
Inventor
デイヴィッド、 エイ ディル、
デイヴィッド、 エイ ディル、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/560,665 external-priority patent/US8445011B2/en
Priority claimed from US13/800,761 external-priority patent/US20130196012A1/en
Priority claimed from US13/847,940 external-priority patent/US8703184B2/en
Application filed by Individual filed Critical Individual
Publication of JP2015522659A publication Critical patent/JP2015522659A/ja
Publication of JP2015522659A5 publication Critical patent/JP2015522659A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015524292A 2012-07-27 2013-06-28 夜尿症のための医薬製剤およびその使用の方法 Pending JP2015522659A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US13/560,665 US8445011B2 (en) 2010-07-08 2012-07-27 Delayed-release formulation for reducing the frequency of urination and method of use thereof
US13/560,665 2012-07-27
US13/800,761 2013-03-13
US13/800,761 US20130196012A1 (en) 2010-11-30 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/847,940 US8703184B2 (en) 2010-07-08 2013-03-20 Delayed-release formulation for reducing the frequency of urination and method of use thereof
US13/847,940 2013-03-20
PCT/US2013/048627 WO2014018223A1 (en) 2012-07-27 2013-06-28 Pharmaceutical formulation for bedwetting and method of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018078173A Division JP2018127482A (ja) 2012-07-27 2018-04-16 夜尿症のための医薬製剤およびその使用の方法

Publications (2)

Publication Number Publication Date
JP2015522659A true JP2015522659A (ja) 2015-08-06
JP2015522659A5 JP2015522659A5 (https=) 2016-07-28

Family

ID=49997724

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015524292A Pending JP2015522659A (ja) 2012-07-27 2013-06-28 夜尿症のための医薬製剤およびその使用の方法
JP2015524291A Pending JP2015522658A (ja) 2012-07-27 2013-06-28 排尿頻度を減少させるための医薬製剤およびその使用の方法
JP2017204851A Pending JP2018039831A (ja) 2012-07-27 2017-10-24 排尿頻度を減少させるための医薬製剤およびその使用の方法
JP2018078173A Pending JP2018127482A (ja) 2012-07-27 2018-04-16 夜尿症のための医薬製剤およびその使用の方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2015524291A Pending JP2015522658A (ja) 2012-07-27 2013-06-28 排尿頻度を減少させるための医薬製剤およびその使用の方法
JP2017204851A Pending JP2018039831A (ja) 2012-07-27 2017-10-24 排尿頻度を減少させるための医薬製剤およびその使用の方法
JP2018078173A Pending JP2018127482A (ja) 2012-07-27 2018-04-16 夜尿症のための医薬製剤およびその使用の方法

Country Status (16)

Country Link
US (3) US20160022615A1 (https=)
EP (3) EP2844241A4 (https=)
JP (4) JP2015522659A (https=)
KR (2) KR20150048741A (https=)
CN (4) CN104470522A (https=)
AU (3) AU2013293488B2 (https=)
BR (2) BR112014031306A2 (https=)
CA (2) CA2875818A1 (https=)
HK (4) HK1205931A1 (https=)
IL (3) IL236028A0 (https=)
MX (2) MX2015001188A (https=)
MY (1) MY171526A (https=)
RU (3) RU2015106672A (https=)
SG (2) SG11201500601QA (https=)
WO (2) WO2014018223A1 (https=)
ZA (2) ZA201408993B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201805810PA (en) * 2015-09-01 2018-08-30 Wellesley Pharmaceuticals Llc Extended, delayed and immediate release formulation method of manufacturing and use thereof
CN108391420A (zh) * 2015-09-30 2018-08-10 韦尔斯利医药有限公司 用于减少排尿频率的组合物及其制备方法和应用
JP2018529710A (ja) * 2015-09-30 2018-10-11 ウェルズリー ファーマスーティカルズ、エルエルシー 排尿の頻度を低減するための組成物、ならびにその作製および使用方法
TW201726114A (zh) * 2015-11-23 2017-08-01 魏斯理製藥公司 降低排尿頻率之組成物、其製備方法、及其應用
EP3706726A4 (en) * 2017-11-07 2021-07-28 Poviva Corp. FOOD AND BEVERAGE COMPOSITIONS WITH PDE5 INHIBITORS
MX2023009833A (es) 2021-02-23 2023-09-04 Otsuka Pharma Co Ltd Formulaciones farmaceuticas de cetanafadina y metodos para prepararlas y utlizarlas.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120164193A1 (en) * 2010-07-08 2012-06-28 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140027B1 (en) * 1998-12-23 2005-10-12 Alza Corporation Dosage forms comprising porous particles
EP1214038A2 (en) * 1999-09-09 2002-06-19 Androsolutions, Inc. Methods and compositions for preventing and treating prostate disorders
EP1313478A2 (en) * 2000-08-30 2003-05-28 Lilly Icos LLC Method for treatment of migraine using pde5 inhibitors
WO2003029199A1 (en) * 2001-09-28 2003-04-10 Takeda Chemical Industries, Ltd. Benzene derivatives, process for preparing the same and use thereof
KR20050005410A (ko) * 2002-02-19 2005-01-13 파마시아 코포레이션 요실금 치료용으로서의 시클로옥시게나제 저해제 및항무스카린제의 용도
AU2003291302A1 (en) * 2002-11-06 2004-06-03 Azaya Therapeutics, Inc. Method for treatment of premature ejaculation in humans
CA2646729A1 (en) * 2005-03-21 2006-09-28 Dov Pharmaceutical, Inc. Methods and compositions for the treatment of urinary incontinence
EP1741444A1 (en) * 2005-07-05 2007-01-10 Jerini AG Kinin antagonists for treating bladder dysfunction
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
WO2007083323A2 (en) * 2006-01-23 2007-07-26 Panacea Biotec Limited. Modified release oral dosage form comprising desmopressin
WO2007113243A2 (en) * 2006-03-31 2007-10-11 Investigación Y Clínica Andrológicas S.L. Use of pde 5 inhibitors for the treatment of overactive bladder
JP5451613B2 (ja) * 2007-08-06 2014-03-26 アラーガン、インコーポレイテッド デスモプレシン薬物送達のための方法及びデバイス
CN101664555A (zh) * 2008-09-02 2010-03-10 许洁 用于治疗泌尿生殖系统感染性疾病的联合药物组合物
CN102028693A (zh) * 2009-09-30 2011-04-27 梁超峰 含有5-型磷酸二酯酶抑制剂的直肠给药组合物
US9260424B2 (en) * 2009-10-26 2016-02-16 Auspex Pharmaceuticals, Inc. 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
US20120135050A1 (en) * 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US20120141554A1 (en) * 2010-07-08 2012-06-07 Wellesley Pharmaceuticals, Llc Delayed release formulation for reducing the frequency of urination and method of use thereof
US8236856B2 (en) * 2010-07-08 2012-08-07 Wellesley Pharmaceuticals, Llc Delayed release formulation for reducing the frequency of urination and method of use thereof
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120164193A1 (en) * 2010-07-08 2012-06-28 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PROSTATE CANCER AND PROSTATIC DISEASE, vol. 12, JPN6017017850, 2009, pages 316 - 324, ISSN: 0003660948 *

Also Published As

Publication number Publication date
AU2013293488B2 (en) 2018-05-17
KR20150048741A (ko) 2015-05-07
WO2014018222A1 (en) 2014-01-30
EP2844241A1 (en) 2015-03-11
RU2015106672A (ru) 2016-09-20
EP2844241A4 (en) 2015-04-29
JP2018039831A (ja) 2018-03-15
CA2879640A1 (en) 2014-01-03
WO2014018223A1 (en) 2014-01-30
AU2018208765A1 (en) 2018-08-16
MY171526A (en) 2019-10-16
CA2875818A1 (en) 2014-01-30
BR112014031306A2 (pt) 2017-06-27
US20160022615A1 (en) 2016-01-28
CN104470522A (zh) 2015-03-25
MX2015001190A (es) 2015-05-07
EP2877179A4 (en) 2016-03-02
JP2018127482A (ja) 2018-08-16
AU2013293489B2 (en) 2017-09-07
CN107661326A (zh) 2018-02-06
ZA201408993B (en) 2016-09-28
HK1205931A1 (en) 2015-12-31
CN107335057A (zh) 2017-11-10
RU2019101864A (ru) 2019-03-11
AU2013293488A2 (en) 2015-02-26
EP2877179A1 (en) 2015-06-03
HK1250628A1 (zh) 2019-01-11
AU2013293488A1 (en) 2015-02-19
RU2015106762A (ru) 2016-09-20
HK1246203A1 (zh) 2018-09-07
SG11201500578VA (en) 2015-03-30
BR112015001627A2 (pt) 2017-07-04
AU2013293489A1 (en) 2015-03-12
ZA201500459B (en) 2016-09-28
IL236622A0 (en) 2015-02-26
KR20150048740A (ko) 2015-05-07
MX2015001188A (es) 2015-05-07
JP2015522658A (ja) 2015-08-06
SG11201500601QA (en) 2015-04-29
EP3527204A1 (en) 2019-08-21
IL261232A (en) 2018-10-31
US20170100351A1 (en) 2017-04-13
US20180344674A1 (en) 2018-12-06
HK1205932A1 (en) 2015-12-31
CN104540505A (zh) 2015-04-22
IL236028A0 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
US20130196012A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
JP2020037575A (ja) 排尿頻度を減少させるための延長放出製剤およびその使用の方法
JP2018024693A (ja) 排尿頻度を減少させるための延長放出製剤およびその使用方法
JP2018127482A (ja) 夜尿症のための医薬製剤およびその使用の方法
US20170319579A1 (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US10799554B2 (en) Pharmaceutical formulation for bedwetting and method of use thereof
JP2018529711A (ja) 排尿の頻度を低減するための組成物、ならびにその作製および使用方法
JP2018526441A (ja) 延長、遅延および即時放出製剤、ならびにその製造および使用方法
US10792326B2 (en) Pharmaceutical formulation for bedwetting and method of use thereof
US20180311186A1 (en) Pharmaceutical formulation for bedwetting and method of use thereof
JP2018538279A (ja) 排尿の頻度を低減するための組成物、ならびにその作製および使用方法
JP2018529710A (ja) 排尿の頻度を低減するための組成物、ならびにその作製および使用方法
HK1187241A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
TW201328724A (zh) 用於減少排尿頻率的延長釋放製劑及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180612